In an open-label, multicenter, stage II study, RC48 verified clinically significant responses and survival benefits in intensively treated patients with locally advanced or metastatic HER2-overexpressing GC, achieving an ORR of 24.8% (102). The gene discussed is ERBB2; the disease is gastric cancer.